Adenofibroma

Summary

Adenofibroma (MONDO:0006071) is a disease (an umbrella term covering 6 Mondo subtypes). A subtype of benign female reproductive system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adenofibroma
Mondo ID	MONDO:0006071
EFO	EFO:1000070
MeSH	D000232
DOID	DOID:2683
NCIT	C8984
UMLS	C0001422
MedGen	1325
Is cancer (heuristic)	no

Also known as: adenofibroma, benign · adenofibroma, no ICD-O subtype · adenofibroma, no ICD-O subtype (morphologic abnormality) · benign mixed Muellerian tumor · benign mixed Muellerian tumour · female reproductive system adenofibroma

Disease family

This is a subtype of benign female reproductive system neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign reproductive system neoplasm › benign female reproductive system neoplasm › adenofibroma

Related subtypes (6): uterine benign neoplasm, vulvar benign neoplasm, fallopian tube benign neoplasm, ovarian benign neoplasm, benign vaginal neoplasm, adenomyoma

Subtypes (6): mucinous adenofibroma, uterine corpus adenofibroma, clear cell adenofibroma, papillary adenofibroma, cystadenofibroma, serous adenofibroma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.